Sorafenib Active Not Recruiting Phase 1 / 2 Trials for Hepatocellular,Carcinoma / HCC / Liver Cancer Treatment

Active Not RecruitingTreatment1 / 2 IdentifierTitleDrugs
NCT02988440Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
NCT02240433A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
NCT00892658Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)